Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

CANbridge to Start Trial of Novel Complement Dysfunction Therapy

publication date: Dec 18, 2020

Beijing CANbridge Pharma, a rare disease company, announced approval to start Singapore clinical trials of its monoclonal antibody targeting complement C5 of the complement system. The first trial for CAN106 will be in patients with paroxysmal nocturnal hemoglobinuria (PNH), a fatal disease in which the complement system destroys red blood cells. As part of an immune response, the complement system helps antibodies and phagocytic cells clear microbes and damaged cells. Dysregulation of the system leads to several rare diseases, including PNH. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital